Skip to content

Author

L. Stein Gold

We have 3 of 341 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Ruxolitinib Cream Improves Clinical Outcomes in Moderate-to-Severe Non-Atopic Chronic Hand Eczema: Responses by Subtype

Chronic hand eczema (CHE) is characterized by persistent or recurrent inflammatory lesions on the hands and wrists. Ruxolitinib (Janus kinase [JAK]1/JAK2 inhibitor) cream has demonstrated efficacy in atopic and nonatopic hand eczema. In a phase 2 study in adults with moderate-to-severe nonatopic CHE (NCT05906628), 1.5%...

M. Zirwas, R. Chovatiya, Benjamin D. Ehst et al. · 0 citations
Review Open access Oct 2026

How Patients with Atopic Dermatitis Experience Topical Therapy: A Real-World Analysis of Impact, Treatment Satisfaction, and HCP Communication.

INTRODUCTION Atopic dermatitis (AD) is a chronic, burdensome skin condition with significant impact on quality of life. Topical therapies are recommended as first-line treatment; however, patients with moderate-to-severe disease or inadequate disease control may require escalation to systemic therapy. Despite the centr...

P. Lio, Autumn Burnette, Alexa Hetzel et al. · 0 citations
Oct 2026

52-Week Safety and Disease Control With Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From the Phase 3 TRuE-AD3 Study.

Ruxolitinib cream applied as needed over 44 weeks was well tolerated and demonstrated disease control in children aged 2-11 years, consistent with findings in adolescents and adults.

A. Paller, L. Stein Gold, E. Simpson et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.